Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00925119 · ClinicalTrials.gov registry record · Phase 4
Examining Genetic Influence on Response to Beta-Blocker Medications in People With Type 2 Diabetes
A Phase 4 study, sponsored by University of Maryland, Baltimore.
- Terminated
- Registry status
- Phase 4
- Development phase
- 31
- Enrollment target
NCT00925119 is a Phase 4 study that was terminated before completion, run by University of Maryland, Baltimore. The registered enrollment target is 31 participants.
The verdict
NCT00925119, a Phase 4 study, was terminated before completion, sponsored by University of Maryland, Baltimore.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 31 participants
- Enrollment target
Study Summary
Beta-blockers are medications used to treat cardiovascular disease (CVD) symptoms, including high blood pressure and chest pain. People with diabetes who receive beta-blockers may experience adverse health effects, but the exact cause of why this happens remains unknown. This study will examine the genetic factors that may influence how atenolol, a beta-blocker medication, affects fat breakdown, blood sugar levels, and heart function in people with type 2 diabetes.
Interventions
- DRUG Atenolol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2009-12 |
| Est. Completion | 2014-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00925119
The ClinicalTrials.gov registry entry for NCT00925119 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atenolol is the first listed.
NCT00925119 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00925119 about?
NCT00925119 is a clinical study titled "Examining Genetic Influence on Response to Beta-Blocker Medications in People With Type 2 Diabetes". Beta-blockers are medications used to treat cardiovascular disease (CVD) symptoms, including high blood pressure and chest pain. People with diabetes who receive beta-blockers may experience adverse health effects, but the exact cause of why this happens remains unknown. This study will examine the ...
What is the current status of trial NCT00925119?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 31 participants. The study started on 2009-12. Estimated completion is 2014-05.
What interventions are being tested in trial NCT00925119?
The interventions under investigation include: Atenolol (DRUG).
Who is sponsoring clinical trial NCT00925119?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.